Search results
Results from the WOW.Com Content Network
Crisaborole (chemical name: 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile) is a member of the class of benzoxaboroles characterized by the presence of a boronic acid hemiester with a phenolic ether and a nitrile. [7] Crisaborole crystallizes into two polymorphs that differ in the
Crisaborole (AN2728), a boron-containing drug for the topical treatment of psoriasis and atopic dermatitis. [24] [25] It was approved by the FDA on December 14, 2016 under the brand name Eucrisa for the treatment of mild-to-moderate atopic dermatitis (eczema) in patients 2 years of age and older. [26] Caffeine is a weak, non-selective PDE ...
This page was last edited on 9 February 2024, at 00:17 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Crisaborole, used to treat atopic dermatitis. Glaucine, an aporphine alkaloid, low-potency PDE4 inhibitor, calcium channel blocker, dopamine antagonist and 5-HT2A positive allosteric modulator, used as antitussive in Eastern Europe and Iceland. PDE4 is the major cAMP-metabolizing enzyme found in inflammatory and immune cells.
This page was last edited on 21 September 2024, at 05:45 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
This page was last edited on 1 November 2024, at 12:31 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
This file contains additional information, probably added from the digital camera or scanner used to create or digitize it. If the file has been modified from its original state, some details may not fully reflect the modified file.
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Crisaborole. PubMed provides review articles from the past five years (limit to free review articles)